CD274 and non-small cell lung carcinoma: Currently, the most commonly used indication is first-line monotherapy with pembrolizumab for patients with NSCLC with >50% PD-L1 expression (KEYNOTE-024) [67] and the combination of CT + pembrolizumab for those patients whose PD-L1 expression is <50% (KEYNOTE-189) [68].